{

"episode_title": "PACUPod: Stress Dose Hydrocortisone Tapers in Septic Shock – Retrospective Cohort Review",

"episode_description": "AI-powered literature briefing from PACUPod. This episode reviews a retrospective cohort study published in Hosp Pharm by Gilchrist et al., evaluating how stress-dose hydrocortisone tapers were used in 276 ICU patients with septic shock between 2020 and 2023. Key findings: about half of patients underwent a taper, with the most common method being reduced dosing frequency (56.8%). At 24 hours after taper initiation, vasopressor requirements were higher in the taper group (37.4% vs 21.3%; P = 0.004); at 48 hours, the difference was not statistically significant (20.3% vs 12.9%; P = 0.14). The taper group showed decreased hospital mortality (OR 0.55, 95% CI 0.33–0.92) and ICU mortality (OR 0.47, 95% CI 0.27–0.81) but longer ICU length of stay (OR 1.04, 95% CI 1.02–1.06) and longer duration of mechanical ventilation (OR 1.08, 95% CI 1.03–1.12). The episode situates these findings within the broader context of stress-dose corticosteroids in septic shock, noting meta-analytic benefits for short-term mortality and shock reversal but risks such as hyperglycemia and neuromuscular weakness. Discussion covers timing (early vs late hydrocortisone) and discontinuation strategies (abrupt vs taper), highlighting substantial practice variability and the need for standardized protocols and prospective research. Limitations include the retrospective design and generalizability concerns. Practical takeaways for critical care pharmacists emphasize careful monitoring during taper, balancing short-term hemodynamics with potential